Figure 7.

Variable drug sensitivity of activating EGFR mutations. A, drug response curves of Ba/F3 cells expressing the indicated EGFR variants or EGFP (vector control). Cells were cultured for 3 days in the presence of the indicated concentrations of cetuximab, erlotinib, or afatinib. Cells expressing EGFR variants were cultured in the absence of IL-3, and vector control cells were cultured in the presence of IL-3. B, Western blotting analyses of EGFR phosphorylation at Tyr-1110 in Ba/F3 cells expressing the indicated EGFR variants after treating the cells for 3 h with the indicated concentrations of erlotinib or afatinib. Error bars, S.D.